Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
90Y vs 177Lu DOTATATE in SSTR+ Tumors
NCT04029428Phase 2Unknown
- Sponsor
- University of Warmia and Mazury
- Start
- Nov 2004
- Primary completion
- Jan 2021
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lutetium Lu 177 dotatate in neuroendocrine tumors (NETs), gastroenteropancreatic neuroendocrine tumors (GEP-NETs), Pulmonary carcinoid tumor, pheochromocytoma, Paraganglioma (PGL), sponsored by University of Warmia and Mazury. Status: unknown.
02
Drugs
lutetium Lu 177 dotatate
03
Conditions
neuroendocrine tumors (NETs)gastroenteropancreatic neuroendocrine tumors (GEP-NETs)Pulmonary carcinoid tumorpheochromocytomaParaganglioma (PGL)
Beyond the preview
Go deeper on NCT04029428.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04029428.